Nothing kills a stem cell clinic faster than a regulatory problem. One FDA warning letter, one state medical board investigation, and you're spending $50,000+ on attorneys instead of treating patients.
The regulatory landscape for regenerative medicine is complex and still evolving. This guide won't replace a healthcare attorney — you absolutely need one. But it will help you understand what you're dealing with and ask the right questions.
The FDA Framework (US Clinics)
The FDA regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under two main categories:
Section 361 Products (Lower Regulation)
These are minimally manipulated cells used for homologous purposes (same function in the body). Think: bone marrow aspirate concentrate injected into a joint to treat joint disease. These don't require FDA premarket approval but do need to meet specific criteria:
- Minimal manipulation of the cells
- Homologous use only
- No combination with another article
- Either no systemic effect or for autologous use, for first/second degree relatives, or for reproductive use
Section 351 Products (Higher Regulation)
If your product doesn't meet all 361 criteria, it's regulated as a drug or biologic under Section 351. This means you need an IND (Investigational New Drug) application and FDA approval before marketing. Most expanded or culture-grown cells, allogeneic products, and cells used for non-homologous purposes fall here.
What This Means Practically
- PRP is generally safe — it's minimally manipulated autologous blood product used homologously
- Same-day bone marrow aspirate — generally 361 if used for musculoskeletal conditions
- Adipose-derived cells — FDA has taken enforcement action against clinics using enzymatically digested fat (SVF) as this is considered more than minimal manipulation
- Allogeneic products (Wharton's jelly, exosomes) — regulatory status varies; some products are marketed under 361 exemptions but this is contested
State-Level Regulations
Beyond the FDA, your state medical board has its own rules about:
- Who can perform regenerative medicine procedures (MD, DO, NP, PA?)
- Advertising claims for stem cell treatments
- Informed consent requirements specific to experimental or novel treatments
- Lab processing requirements (CLIA certification, etc.)
- Facility standards
These vary dramatically by state. Texas has different rules than California, which has different rules than Florida. Check your specific state.
Informed Consent Best Practices
Your consent documents should include:
- Clear description of the proposed treatment
- Expected benefits and realistic outcome expectations
- Known risks and potential complications
- Alternative treatments available
- Statement that the treatment is not FDA-approved (if applicable)
- Statement that insurance will not cover the treatment
- Patient acknowledgment that they understand all of the above
Have a healthcare attorney draft your consent forms. Don't copy another clinic's forms — they may have errors, and your protocols may differ.
Advertising Compliance
This is where most clinics get in trouble. Rules of thumb:
- Don't claim to cure anything. "Stem cell therapy for knee arthritis" is fine. "Cure your arthritis with stem cells" is not.
- Don't use the word "stem cell" if you're not actually using stem cells. Exosomes are not stem cells. PRP is not stem cell therapy.
- Be careful with testimonials. Patient testimonials are powerful but can create implied claims. Add disclaimers about individual results varying.
- Don't make claims your evidence can't support. If you have 50 patients with good outcomes, don't say your treatment has a "95% success rate."
Documentation as Compliance
Your best defense against any regulatory inquiry is thorough documentation. For every patient:
- Signed informed consent
- Complete medical history and examination
- Treatment protocol documentation
- Outcome assessments at follow-up
- Adverse event reporting if anything goes wrong
ClinicTech's digital intake and documentation system creates a complete, timestamped record for every patient interaction — from consent through follow-up. It's not just good operations; it's compliance infrastructure that protects your clinic.
The Bottom Line
Compliance isn't optional, and it's not something you figure out after you open. Build it into your clinic from day one: hire a healthcare attorney, understand your regulatory position, document everything, and advertise honestly. The clinics that thrive long-term are the ones that take compliance seriously from the start.